Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depression | 9 | 2026 | 479 | 1.350 |
Why?
|
| Depressive Disorder | 8 | 2026 | 177 | 1.260 |
Why?
|
| Health Care Costs | 5 | 2024 | 192 | 1.250 |
Why?
|
| Chronic Pain | 5 | 2024 | 125 | 1.170 |
Why?
|
| Gastroenteritis | 2 | 2024 | 16 | 1.020 |
Why?
|
| Cost-Benefit Analysis | 10 | 2023 | 229 | 0.960 |
Why?
|
| Delivery of Health Care, Integrated | 6 | 2024 | 515 | 0.920 |
Why?
|
| Behavior Therapy | 8 | 2026 | 121 | 0.920 |
Why?
|
| Cost of Illness | 2 | 2024 | 90 | 0.900 |
Why?
|
| Humans | 62 | 2026 | 16832 | 0.870 |
Why?
|
| Adolescent | 31 | 2026 | 3464 | 0.820 |
Why?
|
| Neoplasms | 6 | 2026 | 447 | 0.780 |
Why?
|
| Male | 41 | 2026 | 9556 | 0.760 |
Why?
|
| Female | 46 | 2026 | 12193 | 0.730 |
Why?
|
| Anxiety Disorders | 7 | 2026 | 96 | 0.730 |
Why?
|
| Hallucinogens | 1 | 2022 | 21 | 0.690 |
Why?
|
| Quality of Life | 7 | 2025 | 477 | 0.680 |
Why?
|
| Cannabis | 1 | 2022 | 79 | 0.630 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 215 | 0.620 |
Why?
|
| Stroke | 1 | 2022 | 297 | 0.590 |
Why?
|
| Child | 15 | 2026 | 2433 | 0.530 |
Why?
|
| Middle Aged | 21 | 2026 | 7515 | 0.520 |
Why?
|
| Depressive Disorder, Major | 5 | 2022 | 95 | 0.520 |
Why?
|
| Anxiety | 5 | 2026 | 154 | 0.480 |
Why?
|
| Early Detection of Cancer | 3 | 2026 | 553 | 0.470 |
Why?
|
| Colorectal Neoplasms | 3 | 2026 | 635 | 0.450 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 353 | 0.440 |
Why?
|
| Analgesics, Opioid | 4 | 2022 | 239 | 0.440 |
Why?
|
| Aged | 13 | 2026 | 5901 | 0.410 |
Why?
|
| Adult | 20 | 2026 | 7255 | 0.410 |
Why?
|
| Serotonin Uptake Inhibitors | 4 | 2020 | 45 | 0.410 |
Why?
|
| Binge-Eating Disorder | 2 | 2010 | 13 | 0.400 |
Why?
|
| Treatment Outcome | 13 | 2026 | 1098 | 0.380 |
Why?
|
| Young Adult | 12 | 2026 | 2456 | 0.370 |
Why?
|
| Delivery of Health Care | 2 | 2018 | 374 | 0.370 |
Why?
|
| Psychotherapy, Brief | 2 | 2026 | 19 | 0.360 |
Why?
|
| Electronic Health Records | 6 | 2021 | 702 | 0.360 |
Why?
|
| United States | 11 | 2025 | 3858 | 0.340 |
Why?
|
| Reminder Systems | 2 | 2025 | 76 | 0.330 |
Why?
|
| Acupuncture Therapy | 3 | 2017 | 34 | 0.320 |
Why?
|
| Telemedicine | 2 | 2024 | 190 | 0.320 |
Why?
|
| Musculoskeletal Pain | 3 | 2017 | 26 | 0.320 |
Why?
|
| Chronic Disease | 3 | 2022 | 382 | 0.290 |
Why?
|
| Dental Facilities | 1 | 2009 | 1 | 0.290 |
Why?
|
| Primary Health Care | 7 | 2022 | 693 | 0.290 |
Why?
|
| Referral and Consultation | 2 | 2017 | 147 | 0.290 |
Why?
|
| Tobacco Use Cessation | 1 | 2009 | 16 | 0.280 |
Why?
|
| Health Plan Implementation | 1 | 2009 | 34 | 0.280 |
Why?
|
| Genetic Carrier Screening | 2 | 2018 | 15 | 0.280 |
Why?
|
| Combined Modality Therapy | 7 | 2014 | 103 | 0.280 |
Why?
|
| Text Messaging | 2 | 2025 | 39 | 0.270 |
Why?
|
| Surveys and Questionnaires | 7 | 2025 | 1204 | 0.270 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 1058 | 0.270 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 2 | 2022 | 6 | 0.270 |
Why?
|
| Hotlines | 1 | 2007 | 10 | 0.270 |
Why?
|
| Tobacco Use Disorder | 1 | 2007 | 32 | 0.260 |
Why?
|
| Nicotine | 1 | 2007 | 25 | 0.260 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2020 | 35 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 677 | 0.260 |
Why?
|
| Smoking Cessation | 1 | 2007 | 140 | 0.240 |
Why?
|
| Medicare | 2 | 2025 | 188 | 0.240 |
Why?
|
| Antidepressive Agents | 3 | 2018 | 140 | 0.230 |
Why?
|
| Exercise | 4 | 2021 | 513 | 0.230 |
Why?
|
| Video Recording | 1 | 2025 | 18 | 0.230 |
Why?
|
| Child, Preschool | 3 | 2024 | 1430 | 0.220 |
Why?
|
| Social Security | 1 | 2005 | 1 | 0.220 |
Why?
|
| Health Services Research | 3 | 2018 | 180 | 0.220 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 174 | 0.220 |
Why?
|
| Community Health Centers | 1 | 2025 | 58 | 0.220 |
Why?
|
| Needs Assessment | 1 | 2025 | 64 | 0.220 |
Why?
|
| Taxes | 1 | 2005 | 23 | 0.210 |
Why?
|
| Rural Population | 1 | 2024 | 58 | 0.210 |
Why?
|
| History, 21st Century | 1 | 2024 | 24 | 0.210 |
Why?
|
| Occult Blood | 1 | 2025 | 161 | 0.210 |
Why?
|
| Health Care Reform | 1 | 2003 | 19 | 0.200 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2003 | 22 | 0.200 |
Why?
|
| Manipulation, Chiropractic | 2 | 2015 | 18 | 0.200 |
Why?
|
| Acute Disease | 1 | 2024 | 144 | 0.200 |
Why?
|
| Mass Screening | 2 | 2026 | 670 | 0.190 |
Why?
|
| Infant | 2 | 2024 | 1212 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2022 | 2396 | 0.190 |
Why?
|
| Rotavirus | 1 | 2022 | 17 | 0.190 |
Why?
|
| Rotavirus Infections | 1 | 2022 | 33 | 0.190 |
Why?
|
| Rotavirus Vaccines | 1 | 2022 | 53 | 0.180 |
Why?
|
| Vomiting | 1 | 2022 | 11 | 0.180 |
Why?
|
| Patient Acuity | 1 | 2022 | 9 | 0.180 |
Why?
|
| Hawaii | 1 | 2022 | 62 | 0.180 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2012 | 17 | 0.170 |
Why?
|
| Suicide, Attempted | 1 | 2022 | 92 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 12 | 0.170 |
Why?
|
| Accelerometry | 1 | 2021 | 48 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2017 | 100 | 0.160 |
Why?
|
| Cancer Survivors | 2 | 2019 | 114 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 165 | 0.160 |
Why?
|
| Oregon | 3 | 2026 | 168 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2018 | 41 | 0.150 |
Why?
|
| Self Care | 2 | 2011 | 139 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2019 | 262 | 0.150 |
Why?
|
| Survivorship | 1 | 2019 | 13 | 0.150 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2024 | 63 | 0.150 |
Why?
|
| Railroads | 1 | 2019 | 3 | 0.150 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2018 | 9 | 0.140 |
Why?
|
| Neonatal Screening | 1 | 2018 | 12 | 0.140 |
Why?
|
| Health Surveys | 1 | 2019 | 226 | 0.140 |
Why?
|
| Environment Design | 1 | 2019 | 65 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 33 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 19 | 0.130 |
Why?
|
| Genomics | 1 | 2018 | 54 | 0.130 |
Why?
|
| Health Behavior | 3 | 2012 | 332 | 0.130 |
Why?
|
| Life Style | 2 | 2012 | 305 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 653 | 0.130 |
Why?
|
| Cyclohexanols | 3 | 2012 | 19 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2018 | 69 | 0.130 |
Why?
|
| Program Evaluation | 2 | 2009 | 211 | 0.130 |
Why?
|
| Internet | 2 | 2009 | 207 | 0.130 |
Why?
|
| Parents | 2 | 2020 | 298 | 0.130 |
Why?
|
| Psychology, Adolescent | 1 | 2016 | 11 | 0.120 |
Why?
|
| Propensity Score | 1 | 2017 | 78 | 0.120 |
Why?
|
| Drug Costs | 1 | 2016 | 32 | 0.120 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 21 | 0.120 |
Why?
|
| Child of Impaired Parents | 1 | 2015 | 27 | 0.110 |
Why?
|
| Weight Loss | 2 | 2022 | 302 | 0.110 |
Why?
|
| Patient Navigation | 2 | 2025 | 20 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2023 | 1186 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 186 | 0.110 |
Why?
|
| Retrospective Studies | 6 | 2022 | 2463 | 0.110 |
Why?
|
| Commerce | 1 | 2014 | 37 | 0.100 |
Why?
|
| Buprenorphine | 1 | 2014 | 50 | 0.100 |
Why?
|
| Risk Factors | 3 | 2026 | 3108 | 0.100 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2013 | 23 | 0.100 |
Why?
|
| Phenotype | 1 | 2013 | 105 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2016 | 235 | 0.100 |
Why?
|
| Health Maintenance Organizations | 3 | 2015 | 358 | 0.100 |
Why?
|
| Adolescent Behavior | 2 | 2012 | 118 | 0.100 |
Why?
|
| Anhedonia | 1 | 2012 | 4 | 0.090 |
Why?
|
| Counseling | 2 | 2014 | 170 | 0.090 |
Why?
|
| Bulimia | 1 | 2011 | 8 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 520 | 0.080 |
Why?
|
| Pharmacists | 2 | 2021 | 53 | 0.080 |
Why?
|
| Manuals as Topic | 1 | 2010 | 5 | 0.080 |
Why?
|
| Suicide | 1 | 2012 | 114 | 0.080 |
Why?
|
| Bone Density | 2 | 2008 | 93 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 317 | 0.080 |
Why?
|
| Overweight | 1 | 2012 | 262 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 290 | 0.070 |
Why?
|
| Diet | 2 | 2012 | 349 | 0.070 |
Why?
|
| Self-Help Groups | 1 | 2009 | 22 | 0.070 |
Why?
|
| Translational Medical Research | 1 | 2009 | 24 | 0.070 |
Why?
|
| Hospitalization | 2 | 2025 | 816 | 0.070 |
Why?
|
| Advertising as Topic | 1 | 2007 | 9 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 1233 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2008 | 161 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2009 | 186 | 0.070 |
Why?
|
| Telephone | 1 | 2009 | 157 | 0.070 |
Why?
|
| Feeding and Eating Disorders | 1 | 2007 | 16 | 0.070 |
Why?
|
| Smoking Prevention | 1 | 2007 | 32 | 0.070 |
Why?
|
| Venlafaxine Hydrochloride | 3 | 2012 | 20 | 0.060 |
Why?
|
| Health Services | 1 | 2007 | 100 | 0.060 |
Why?
|
| Northwestern United States | 2 | 2021 | 53 | 0.060 |
Why?
|
| Time Factors | 3 | 2016 | 989 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 1887 | 0.060 |
Why?
|
| Los Angeles | 1 | 2026 | 139 | 0.060 |
Why?
|
| California | 2 | 2025 | 2244 | 0.060 |
Why?
|
| Investments | 1 | 2005 | 1 | 0.060 |
Why?
|
| Social Isolation | 1 | 2025 | 20 | 0.050 |
Why?
|
| Safety-net Providers | 1 | 2025 | 52 | 0.050 |
Why?
|
| Feces | 1 | 2025 | 90 | 0.050 |
Why?
|
| Washington | 1 | 2026 | 376 | 0.050 |
Why?
|
| Health Promotion | 1 | 2007 | 277 | 0.050 |
Why?
|
| Psychometrics | 2 | 2017 | 114 | 0.050 |
Why?
|
| Pain Management | 1 | 2024 | 56 | 0.050 |
Why?
|
| Budgets | 1 | 2003 | 5 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2026 | 571 | 0.050 |
Why?
|
| Insurance Benefits | 1 | 2003 | 12 | 0.050 |
Why?
|
| Pandemics | 1 | 2026 | 289 | 0.050 |
Why?
|
| Prevalence | 1 | 2026 | 785 | 0.050 |
Why?
|
| Deductibles and Coinsurance | 1 | 2003 | 31 | 0.050 |
Why?
|
| Age Factors | 1 | 2005 | 814 | 0.050 |
Why?
|
| Veterans | 1 | 2024 | 143 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 137 | 0.050 |
Why?
|
| Child Health | 1 | 2023 | 41 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 99 | 0.050 |
Why?
|
| Patient Health Questionnaire | 1 | 2022 | 18 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2022 | 176 | 0.040 |
Why?
|
| Drug Resistance | 2 | 2012 | 19 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 393 | 0.040 |
Why?
|
| Vital Signs | 1 | 2021 | 12 | 0.040 |
Why?
|
| Biomarkers | 2 | 2016 | 284 | 0.040 |
Why?
|
| Sleep Hygiene | 1 | 2020 | 2 | 0.040 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 6 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 352 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2011 | 71 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 132 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 120 | 0.040 |
Why?
|
| Communication | 1 | 2021 | 183 | 0.040 |
Why?
|
| Mentoring | 1 | 2019 | 29 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 103 | 0.040 |
Why?
|
| Religion and Medicine | 1 | 2018 | 2 | 0.040 |
Why?
|
| Reproductive Health | 1 | 2018 | 10 | 0.030 |
Why?
|
| Income | 1 | 2018 | 81 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 319 | 0.030 |
Why?
|
| Preconception Care | 1 | 2018 | 43 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 305 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2016 | 14 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 244 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 995 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 12 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 2016 | 30 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2016 | 8 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2012 | 925 | 0.030 |
Why?
|
| Models, Economic | 1 | 2016 | 16 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2016 | 35 | 0.030 |
Why?
|
| Health Resources | 1 | 2016 | 35 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 167 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 828 | 0.030 |
Why?
|
| Actigraphy | 1 | 2015 | 14 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 80 | 0.030 |
Why?
|
| Utilization Review | 1 | 2014 | 33 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 453 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 210 | 0.030 |
Why?
|
| Cognition | 1 | 2015 | 90 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 155 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 1047 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 1555 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2012 | 10 | 0.020 |
Why?
|
| Drug Substitution | 1 | 2012 | 9 | 0.020 |
Why?
|
| Affect | 1 | 2012 | 21 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 33 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 138 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 54 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2012 | 55 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 104 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 62 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 175 | 0.020 |
Why?
|
| Anorexia Nervosa | 1 | 2010 | 5 | 0.020 |
Why?
|
| Bulimia Nervosa | 1 | 2010 | 10 | 0.020 |
Why?
|
| Cost Savings | 1 | 2010 | 20 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 44 | 0.020 |
Why?
|
| Outcome Assessment (Health Care) | 1 | 2011 | 199 | 0.020 |
Why?
|
| Suicidal Ideation | 1 | 2011 | 98 | 0.020 |
Why?
|
| Retention (Psychology) | 1 | 2008 | 4 | 0.020 |
Why?
|
| Calcium | 1 | 2008 | 27 | 0.020 |
Why?
|
| Managed Care Programs | 1 | 2010 | 275 | 0.020 |
Why?
|
| Office Visits | 1 | 2007 | 78 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2007 | 70 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Naltrexone | 1 | 2006 | 16 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2006 | 56 | 0.020 |
Why?
|
| Comorbidity | 1 | 2007 | 516 | 0.010 |
Why?
|
Concepts
(249)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(23)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->